back to press releases

Dr. Martin Madaus Joins Quanterix Board Of Directors

Cambridge, MA – Quanterix Corporation announced today that Martin D. Madaus, Ph.D has joined the company’s Board as Executive Chairman. Dr. Madaus brings more than 20 years of experience in the diagnostics and life science industries, most recently serving as President, Chairman and CEO of Millipore Corporation, recently acquired by Merck KGaA.

“Martin brings significant expertise, both strategic and commercial, that will be invaluable to Quanterix as we launch the company’s Single Molecule Array (SiMoA™) technology in both the diagnostics and life science research markets.” said David Okrongly, Ph.D, President and CEO of Quanterix.

“The application of SiMoA holds tremendous promise for clinical diagnostics, allowing earlier detection of disease, improved disease monitoring and better patient outcomes,” said Dr. Martin Madaus. “Furthermore, the 1,000-fold improvement in sensitivity realized by SiMoA will not only allow existing proteins to be measured with increased accuracy, precision, and speed, but will also enable validation of the potentially thousands of serum proteins that until now have proven elusive. This is a game changing technology, and I look forward to working with the Quanterix board and management team to realize the full potential of SiMoA.”

Before joining Millipore, Dr. Madaus was President, CEO and head of North American Operations for Roche Diagnostics Corporation. Prior to this he served as VP of Business Development for Roche Molecular Diagnostics and General Manager of Boehringer Mannheim Canada. He is also a director of the Massachusetts High Technology Council and serves on the Life Sciences Collaborative Leadership Council of the Massachusetts Technology Collaborative.

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) platform technology for the in vitro diagnostics and life science research markets, enabling single molecule measurement of proteins, nucleic acids and cells. The digital nature of SiMoA delivers unprecedented assay performance, yielding more than 1,000-fold greater sensitivity compared with today’s immunoassay systems, while also providing important advantages in precision, speed and cost. Researchers in life science will also benefit from application of SiMoA to validate novel, low abundance biomarkers in blood, leading to the development of new in vitro diagnostic tests that will offer clinicians greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit